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Abstract
Background: This study aims to evaluate the feasibility and 
safety of resection of sarcoma liver metastases, and to iden-
tify possible prognostic factors for long-term survival. Meth-
ods: All patients who underwent resection of liver metasta-
ses of sarcoma in the Netherlands from 1998 to 2014 were 
included. Study data was retrospectively collected from pa-
tient files. Survival rates were calculated using Kaplan-Meier 
survival analysis. Results: Some 38 patients treated in 16 
hospitals were included (15 male, 23 female). The median 
age was 57 years (37–80 years). The most common histolog-
ical subtype was leiomyosarcoma (63%). The predominant 
site of primary tumour was the abdomen (59%). R0 resection 
was achieved in 16 patients. Mortality was 3 and 16% of in-
cluded patients had 1 or more complications. The median 
follow-up period was 18 months (range 1–161). After liver 
resection, 1-, 3-, and 5-year survival were 88, 54, and 42% re-
spectively. Median overall survival was 46 months (1–
161 months). One- and three-year progression-free survival 
(PFS) after liver resection were 54 and 19% respectively. Me-
dian PFS was 16 months (1–61 months). Conclusions: Liver 
surgery for sarcoma metastases is safe and leads to a rela-
tively good survival. The choice for surgical treatment should 
always be discussed in a multidisciplinary sarcoma and liver 
team. © 2018 The Author(s)
Published by S. Karger AG, Basel
Introduction
Sarcomas are held accountable for less than 1% of all 
solid malignancies and approximately 80% of all sarco-
mas originate from soft tissue. Prognosis depends mainly 
on histological factors and patient characteristics. Of all 
patients with soft tissue sarcoma (STS), 25–40% will de-
velop distant metastases [1, 2]. Predominant sites of me-
F.A.B.G. and M.F.J.S. contributed equally to this manuscript.
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
Grimme et al.Dig Surg 2019;36:479–486480
DOI: 10.1159/000493389
tastases are the lungs and liver. Up to 16% of all patients 
with retroperitoneal sarcomas and 62% of all patients 
with visceral sarcomas will develop hepatic metastases 
[2]. The current standard treatment for patients with 
metastatic STS (excluding gastrointestinal stromal tu-
mours, Ewing-like sarcomas, and other small blue round 
cell tumours) is systemic therapy with doxorubicin or if-
osfamide, both resulting in poor survival rates [3, 4]. 
Resection of liver metastases arising from neuroendo-
crine or colorectal carcinoma in patients with liver-only 
disease is widely accepted and effective [5–7]. The role of 
surgery in the treatment of STS with hepatic metastases 
remains unclear. 
Current literature on this subject consists of small, het-
erogeneous cohorts, including patients with metastases 
from gastro intestinal stroma cell tumours (GIST) or oth-
er non-colorectal, non-neuroendocrine tumours. These 
studies demonstrate a possible improved survival after re-
section of metastases [2, 8–12]. To date, no data from a 
population-based national database is reported.  
The objective of this study was to evaluate all patients 
in the Netherlands who underwent liver resection for he-
patic metastases of STS since 1998. Primary outcomes 
were progression-free survival (PFS) and overall survival 
(OS). Secondary aims were demonstrating the safety of 
the procedure, and identification of factors that may in-
fluence long-term survival.
Materials and Methods
Patients and Data
All patients who underwent a liver resection of metastatic STS 
between January 1998 and July 2014 in the Netherlands were iden-
tified via the Dutch nationwide histology database (PALGA). Since 
1991, all reports generated by every pathology department in the 
Netherlands are collected in this nationwide database [13]. All Ew-
ing-like sarcomas and other small blue round cell tumours were 
excluded, since these types of sarcomas respond well to chemo-
therapy. Furthermore, GIST were also excluded. Standard demo-
graphic and clinicopathologic data, including histopathological 
information about the primary tumour and metastases, intraop-
erative details and use of chemo- and/or radiotherapy, were retro-
spectively collected from the patient files in 16 different hospitals 
in the Netherlands. Prior ethical approval was granted for the cur-
rent study, with the medical Ethic Committee waiving the require-
ment for informed consent to be obtained for the use of anony-
mized patient data.
Surgery
Decisions about surgical approaches were tailor-made for ev-
ery single patient. Hepatic metastases were defined according to 
Couinaud’s liver segments [14]. Radicality was defined according 
to the Union Internationale Contre le Cancer standards; R0: com-
plete microscopic resection, R1: microscopic residual disease or 
R2: macroscopic residual hepatic or extrahepatic disease. Liver 
metastases were considered metachronous when they were diag-
nosed at least 6 months after diagnosis of the primary tumour.
Outcome Variables
Primary outcomes in this study were PFS and OS. PFS was de-
fined as the time between resection of liver metastases and the first 
diagnostic proven recurrence or progression of disease in liver or 
any other tissue. OS was defined as the time from first liver resec-
tion till the date of death, regardless of the cause of death. Inciden-
tally, the date of death could not be traced; in that case, the last date 
of follow-up was used. Secondary outcomes included the safety of 
metastasectomy and the prognostic impact of gender, age, the type 
of resection (minor; ≤2 segments or major; > 2 segments), radical-
ity (R0, R1 or R2), the extent of PFS, the number of metastases, the 
time of diagnosis of liver metastases (synchronous or metachro-
nous) on PFS and OS.
Statistical Considerations
PFS and OS were estimated by Kaplan-Meier survival analysis. 
According to Cox proportional hazards regression methodology, 
prognostic factors for long-term survival were identified by uni-
variable survival analysis. A p value of less than 0.05 was consid-
ered statistically significant. All statistical analyses were performed 
using the Statistical Package for the Social Sciences version 23.0 for 
Windows (SPSS, Inc., Chicago, IL, USA).
Results
Demographics and Histological Characteristics
Thirty-eight patients underwent hepatic resection of 
metastatic STS between January 1998 and July 2014. Pa-
tient characteristics are described in Table 1. Liver resec-
tion took place in 16 different hospitals. Twenty-three fe-
male and 15 male patients were included in this study. 
The median age at liver resection was 57 years (range 37–
80 years). In total, 5 histological types of sarcoma were 
described, 7 cases were described as “not otherwise spec-
ified”. All diagnoses were confirmed histologically. The 
median follow-up was 18 months (range 1–161 months) 
after liver resection. 
Preoperative Evaluation of Liver Metastases
All liver metastases were preoperatively diagnosed 
by ultrasound, CT-, MRI-, PET-scanning or a combina-
tion of these means. In 14 patients, multiple liver me-
tastases were found; 20 patients had a solitary metasta-
sis. In 8 patients, metastases were spread bilobar and in 
28 patients, unilobar. Liver metastases were synchro-
nous in 11 patients and metachronous in 23. In 4 pa-
tients data on the number and location of lesions were 
missing.  
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Surgical Procedure
In 3 cases, intraoperative radio frequent ablation 
(RFA) was combined with liver resection. A minor re-
section (≤2 segments) was performed in 24 patients and 
13 patients underwent a major (> 2 segments) resection. 
There was no intra-operative mortality; nevertheless, 3 
patients had intra-operative complications, including a 
perforation of the small bowel, tumour rupture and 
bleeding. In 16 patients, an R0-resection was achieved, 
5 patients underwent an R1-resection and in 15 pa-
tients, surgery resulted in an R2-resection. In 7 patients, 
R2-resection was achieved due to extra hepatic disease. 
In 2 patients, information about radicality was not 
available. 
Postoperative Complications
Six patients encountered postoperative complications, 
for which 2 patients underwent secondary surgery due to 
intra-abdominal sepsis. One of these patients died due to 
sepsis after a gastrointestinal perforation. Median hospi-
tal stay was 9 days (range 2–20 days).
Progression-Free Survival
Median PFS was 16 months (range 1–161; Fig. 1). One- 
and three-year PFS after liver resection were 54.2 and 
18.9% respectively. Follow-up was conducted according 
to the preference of the local centre. One patient did not 
experience progression of disease after 5 years. Median 
PFS after resection of metachronous metastases was sig-
nificantly longer with 19 months (range 1–161 months) 
versus 5 months (range 2–54 months) for synchronous 
metastases (p = 0.02). When an R0- or R1-resection could 
be achieved, median PFS was 16 months (range 2–161 
months); for an R2-resection, median PFS was 10 months 
(range 1–161 months; p = 0.87). Eight patients underwent 
secondary liver resection. Median PFS was 19 months 
(range 1–161 months) for patients younger than 60 and 9 
months (range 2–34 months) for patients older than 60 
(p = 0.06). 
PFS was also not significantly different in terms of gen-
der, number of metastases, primary intra- or extra-ab-
dominal tumour, minor/major resection or uni- or bi-
lobar metastases. Factors that may influence PFS are de-
scribed in Table 2.
Overall Survival
Median OS was 46 months (1–161 months; Fig.  2). 
One-year survival, 3-year survival and 5-year survival af-
ter liver resection were 88.1, 53.9 and 41.1% respectively. 
In the R0- or R1-group, 54.6% of the patients were alive 
after 5 years. Median OS in the R0- or R1-group was 77 
months (range 6–142) and median survival in the R2-
group was 20 months (range 1–161; p = 0.19). Factors 
that  may influence outcome are described in Table 2. 
None of the factors mentioned above could be included 
in multivariable analysis for OS, since all factors had a p 
value of > 0.05 in univariable analysis.
Table 1. Patient and tumour characteristics
Variable (n = 38)
Gender  
Male 15 (40)
Female 23 (60)
Age 57 (37–80)
Sarcoma subtype  
Leiomyosarcoma 24 (63)
Liposarcoma 3 (8)
Hemangiopericytoma 2 (5)
Angiosarcoma 1 (3)
PEComa* 1 (3)
Not otherwise specified 7 (19)
Primary tumour site
Abdomen 22 (59)
Organ (bowel, stomach) 9 (23)
Retroperitoneum 7 (18)
Gynaecologic 6 (15)
Pelvis 1 (3)
Extremity 5 (13)
Head 2 (5)
Other 9 (24)
Interval primary tumour – hepatic metastases  
Synchronous 11 (28)
Metachronous 23 (59)
Missing 4 (10)
Number of hepatic metastases  
Solitary 20 (51)
Multiple 14 (36)
Missing 4 (10)
Distribution metastases  
Unilobar 28 (74)
Bilobar 8 (21)
Missing 2 (5)
Extrahepatic metastases prior to liver resection  
Absent 25 (67)
Present 12 (30)
Missing 1 (3)
Type of resection  
Minor 24 (63)
Major 13 (34)
Missing 1 (3)
For continuous variables data shown represent median (range), 
all other data is presented as numbers (%).* PEComa, perivascular epithelioid cell tumour.
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Discussion
In the current study, liver resection for metastatic 
STS resulted in a median OS of 46 months (1–161 
months). Median PFS after liver resection was 16 
months (1–161  months). Development of metachro-
nous metastases was the only beneficial prognostic fac-
tor for PFS. The sample size of the current study clearly 
illustrates the scarcity of liver resection for hepatic me-
tastases of STS, resulting in a scarcity of studies pub-
lished on this topic. This study is the first nationwide 
report of all patients who underwent liver surgery for 
sarcoma metastases during a period of more than 15 
years in the Netherlands. 
Current treatment options for patients with STS 
metastatic to the liver include chemotherapy, trans-ar-
terial chemotherapy embolization, radiofrequency or 
microwave ablation and hepatectomy. Liver metasta-
sectomy has been previously described to be a curative 
treatment option in a highly selected group of patients 
[10, 15–18].
According to analyses conducted by the European 
 Organization for Research and Treatment of Cancer 
(EORTC), treatment of patients with hepatic STS metas-
tases with chemotherapy alone, resulted in a median OS 
of 10 months with a 1-year survival of 42% and a 2-year 
survival of 13% [15]. Combined chemotherapy (doxoru-
bicin + ifosfamide) has demonstrated not to improve 
OS [4]. Median OS in our, highly selective, cohort was 
46 months with a 1-year survival of 88% and a 2-year sur-
vival of 62% respectively. Hepatectomy should therefore 
be considered a treatment option for a selected group of 
patients.
During the past decades, liver surgery has become safe, 
thereby liberalizing its indications [19]. Especially, 
colorectal liver metastases are frequently operated on in 
the Netherlands, whereas surgery for non-colorectal me-
tastases is still rare [20]. However, it is pivotal to meticu-
lously select patients who are candidates for potentially 
curative resection. Discussion in multidisciplinary tu-
mour boards has demonstrated to be essential in select-
ing patients who might benefit from surgery [21]. The 
results of the current study are comparable to other co-
hort studies (Table 3). Only Groeschl et al. [9] and Chua 
et al. [22] reported a substantially higher OS, with a me-
dian OS of 71 and 103 months respectively.
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Nevertheless, Chua et al. [22] included only 15 patients 
with a large OS range (6–200 months) [22] and Groeschl 
et al. [9] excluded all R1- and R2-resections from their 
analyses. 
Adam et al. [23] identified an age of > 60 years, a PFS 
of < 12 months, R2-resection and major hepatectomy 
as factors associated with poor outcome in a large co-
hort of patients with noncolorectal nonendocrine liv-
er  metastases. In accordance with Adam et al. [23], 
we have shown a trend towards a better PFS and OS 
after an R0- or R1-resection compared to an R2-resec-
tion (Table 2). The statistical insignificance of this dif-
ference may be explained by the relatively small sample 
size. The deteriorated survival rate after an R2-resec-
tion is most likely due to surgery with a palliative in-
tent.  However, median OS after R2 resection is 
20 months (1–161), which is higher than median sur-
vival (10  months) described with chemotherapy in 
EORTC trial [15].
Moreover, patients from our cohort who were treated 
for synchronous metastases had a significant shorter me-
dian PFS than patients treated for metachronous metas-
tases. 
Given the low sample size of this study, no firm con-
clusions can be made in comparison to other historic co-
hort studies.
Other treatment options for sarcoma metastatic to the 
liver are RFA, microwave ablation, trans-arterial chemo 
embolization (TACE), and radioembolization with yttri-
um 90 microspheres. Pawlik et al. [16] showed that RFA 
of metastases resulted in higher recurrence rates than re-
section alone. In our study, only 3 patients received RFA, 
in combination with surgery for metastases; therefore, 
comparisons could not be made. The use of TACE for he-
patic metastases of STS is reported in a few studies [17, 18]. 
Median PFS was reported to be 6 months and median OS 
was 21 months for responders. Therefore, the authors 
conclude that TACE should be reserved as a salvage op-
tion. However, in the study of Maluccio et al. [17] 6 out of 
7 leiomyosarcomas treated did not respond to the therapy. 
STSs represent a large and heterogenic group of tu-
mours. A drawback of this study is that biological behav-
Table 2. Potential prognostic factors for survival
Variable (n = 38) PFS,  
months
Univariable
p value
OS, months Univariable
p value
Gender      
Male 15 (40) 19 0.794 62 0.522
Female 24 (60) 10 35  
Age      
<60 years 23 (61) 19 0.057 62 0.196
≥60 years 15 (29) 9 35  
Interval primary tumor – hepatic metastases      
Synchronous 11 (28) 5 0.021 40 0.508
Metachronous 23 (59) 19 20  
Number of hepatic metastases      
Solitary 20 (51) 10 0.367 62 0.360
Multiple 14 (36) 16 46  
Distribution metastases      
Unilobar 28 (74) 13 0.684 56 0.960
Bilobar 8 (21) 18 20  
Resection status      
RO or R1 21 (55) 16 0.869 77 0.192
R2 15 (39) 10 20  
Type of resection      
Minor 24 (63) 10 0.854 18 0.321
Major 13 (34) 16 56  
Primary tumour site
Intra-abdominal 22 (58) 9 0.364 19 0.099
Extra-abdominal 16 (42) 17 Not reached
PFS, progression-free survival; OS, overall survival.
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Table 3. Survival after hepatic resection for metastatic sarcoma
Study n Follow-up,
median/months
Survival
Jaques et al. [2], 1995 14 60 Median OS 30 months, 5-year OS was 0%*
Harrison et al. [24], 1997 27 60 Median OS 31 months, 5-year OS was 4%*
Elias et al. [25], 1998 13 Unknown 5-Year OS 18%*
Chen et al. [26], 1998 11 53 Median OS 39 months*
Lang et al. [27], 2000 26 Unknown Median OS after R0 resection: 32 months, 5-year OS 13%
DeMatteo et al. [8], 2001 22 25 Median OS 30 months
Pawlik et al. [16], 2006 66 35.8 1-Year OS 91.2%, 5-year OS 27%**
Adam et al. [23], 2006 125 Mean FU: 31 months Median OS 32 months, 5-year OS 31%
Lendoire et al. [28], 2007 23 28 5-Year OS 0%
Rehders et al. [29], 2009 27 84 Median OS 44 months, 5-year OS 49%^
Chua et al. [22], 2011 15 122 Median OS 103 months, 5-year OS: 51%, 10-year OS: 37%^
Marudanayagam et al. [11], 2011 36 24 Median OS 24 months, 5-year OS 32%^
Zacherl et al. [30], 2011 15 Unknown Median OS 34 months, 5-year OS 27%^
Groeschl et al. [9], 2012 98 32 Median OS 72 months, 1-year OS: 82%, 5-year OS 32%***
Brudvik et al. [10], 2015 50 32 Median OS 45 months, 5-year OS 45%, 10-year OS 23%* Study population included before 1996.** Study population included 36 Gastrointestinal stromal tumours, 13 patients were treated with RFA only.*** Excluded all R1- and R2-resections.^ Study population included Sarcomas and Gastrointestinal stromal tumours.
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iour and response to therapy of the different subtypes 
could not be determined because of the small number of 
patients. 
As mentioned above and stated in Table 3, most of the 
previously published studies contain a mixture of infor-
mation on STS and GIST, or other non-colorectal, non-
neuroendocrine tumours [2, 8–11, 16, 22–30]. Due to our 
more homogeneous study group, the outcomes in this 
study are more specific, making them poorly comparable 
to the outcomes of older studies (Table 3). 
The strength of our study is the relatively large sample 
size from a population-based data set. Furthermore, this 
study provides detailed information on intra- and post-
operative complications, which are rare in population-
based data sets. However, certain limitations do apply to 
our current analysis. The current study lacks a proper 
control group. Also, information on postoperative che-
motherapy regimens is lacking. This may explain why 
synchronous liver metastasis was a prognostic factor for 
PFS, without influencing OS. Nevertheless, it is the best 
available evidence since sarcoma, especially with poten-
tially resectable hepatic metastases, is rare and therefore 
comparative studies and clinical trials are difficult to ef-
fectuate. This calls for the need of an international pro-
spective database with results of various treatment mo-
dalities for this group of patients to improve the under-
standing and treatment of the various subtypes of STS.
In conclusion, since current chemotherapy or other 
treatment options do not lead to cure, resection of sar-
coma liver metastases should be considered and discussed 
in a multidisciplinary sarcoma and liver team for all pa-
tients with technically resectable metastases as a potential 
treatment option. Although this may achieve cure, it re-
mains palliative treatment for the majority of the selected 
patients.
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